Gitazone/Gitazone-forte

Gitazone/Gitazone-forte

pioglitazone

Manufacturer:

Millimed

Distributor:

Prosp Pharma
Concise Prescribing Info
Contents
Pioglitazone HCl
Indications/Uses
NIDDM.
Dosage/Direction for Use
Monotherapy 15 or 30 mg. Combination therapy 15 or 30 mg w/ current sulphonylurea, metformin or insulin dose. Max: 45 mg. All doses to be given once daily.
Administration
May be taken with or without food.
Contraindications
NYHA class III or IV heart failure.
Special Precautions
Type 1 diabetes, diabetic ketoacidosis. CHF, symptomatic heart failure, edema, macular edema. Increase incidence of bone fracture especially in women. Ovulation may occur in premenopausal anovulatory women. Periodic monitoring of liver enzymes. Evaluate serum ALT levels prior to initiation of therapy & periodically thereafter. Reduce dose of concomitant antidiabetic therapy if hypoglycemia occurs. Monitor for fluid retention-related adverse events. Childn <18 yr.
Adverse Reactions
Upper resp tract infection, headache, sinusitis, myalgia, tooth disorder, aggravated DM, pharyngitis. Mild to moderate hypoglycemia during combination therapy. Anemia, edema, macular edema, CV events, decreases in Hb & hematocrit, wt gain, reversible elevation in ALT & CPK.
Drug Interactions
Gemfibrozil, rifampicin.
MIMS Class
ATC Classification
A10BG03 - pioglitazone ; Belongs to the class of thiazolidinediones. Used in the treatment of diabetes.
Presentation/Packing
Form
Gitazone tab 15 mg
Packing/Price
3 × 10's
Form
Gitazone-forte tab 30 mg
Packing/Price
10 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in